TITatsuro Ibe

Tatsuro Ibe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tatsuro Ibe has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Hideo Fujita

    Division of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Saitama, Japan

    3 shared publications
  • Hiroshi Wada

    Affiliation Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan

    2 shared publications
  • Hiroyuki Jinnouchi

    Affiliation Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan

    2 shared publications
  • Hisataka Maki

    Affiliation Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan

    2 shared publications
  • Kei Yamamoto

    Affiliation Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan

    2 shared publications
  • Kenichi Sakakura

    Affiliation Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan

    2 shared publications

Latest Publications

  • Clinical Implications of Resting Metabolic Rate in Heart Failure With Preserved Ejection Fraction

    by Tatsuro Ibe, Jwan A. Naser, Tomonari Harada, Atsushi Tada, Shunichi Doi, Yogesh N.V. Reddy, Vojtech Melenovsky, Michael D. Jensen, Barry A. Borlaug

  • Chronic active Epstein-Bar virus infection complicated by pulmonary artery hypertension

    by Yukiko Misaki, Daisuke Minakata, Tatsuro Ibe, Ayumi Gomyo, Kazuki Yoshimura, Shun-Ichi Kimura, Yuhei Nakamura, Masakatsu Kawamura, Shunto Kawamura, Junko Takeshita, et al.


  • Open Access

    Cardiac index predicts long-term outcomes in patients with heart failure

    by Tatsuro Ibe, Hiroshi Wada, Kenichi Sakakura, Yusuke Ugata, Hisataka Maki, Kei Yamamoto, Masaru Seguchi, Yousuke Taniguchi, Hiroyuki Jinnouchi, Hideo Fujita

    Background: The role of cardiac index (CI) and right atrial pressure (RAP) for predicting long-term outcomes of heart failure has not been well established. The aim of this study was to investigate long-term cardiac outcomes in patients with heart failure having various combinations of CI and RAP.Methods: A total of 787 heart failure patients who underwent right-heart catheterization were retrospectively categorized into the following four groups: Preserved CI (≥2.5 L/min/m2) and Low RAP (2) and High RAP (≥8 mmHg) (PRE-CI/H-RAP; n = 242); Reduced CI (2) and Low RAP (2) and High RAP (≥8 mmHg) (RED-CI/H-RAP; n = 137). Survival analysis was applied to investigate which groups were associated with major adverse cardiovascular events (MACE).Results: The RED-CI/L-RAP and RED-CI/H-RAP groups were significantly associated with MACE as compared with the PRE-CI/L-RAP and PRE-CI/H-RAP groups after adjustment for confounding factors (RED-CI/L-RAP vs. PRE-CI/L-RAP: HR 2.11 [95% CI 1.33–3.37],p= 0.002; RED-CI/H-RAP vs. PRE-CI/L-RAP: HR 2.18 [95% CI 1.37–3.49],p= 0.001; RED-CI/L-RAP vs. PRE-CI/H-RAP: HR 1.86 [95% CI 1.16–3.00],p= 0.01; RED-CI/H-RAP vs. PRE-CI/H-RAP: HR 1.92 [95% CI 1.26–2.92],p= 0.002), whereas the difference between the RED-CI/H-RAP and RED-CI/L-RAP groups was not significant (HR 1.03 [95% CI 0.64–1.66],p= 0.89).Conclusions: The hemodynamic severity categorized by CI and RAP levels provided clear risk stratification in patients with symptomatic heart failure. Low CI was an independent predictor of long-term cardiac outcomes.


  • Open Access

    Combined pre- and post-capillary pulmonary hypertension: The clinical implications for patients with heart failure

    by Tatsuro Ibe, Hiroshi Wada, Kenichi Sakakura, Yusuke Ugata, Hisataka Maki, Kei Yamamoto, Masaru Seguchi, Yousuke Taniguchi, Hiroyuki Jinnouchi, Shin-Ichi Momomura, et al.

    Background: The prognostic implications of combined pre- and post-capillary pulmonary hypertension (Cpc-PH) in patients with pulmonary hypertension due to left heart disease (PH-LHD) remain controversial. The aim of this retrospective study was to evaluate the new PH-LHD criteria, recommended by the 6th World Symposium on Pulmonary Hypertension and to determine the prognostic value of Cpc-PH.Methods: A total of 701 patients with symptomatic heart failure who had undergone right-heart catheterization were divided into the following four groups: (i) Isolated post-capillary PH (Ipc-PH) group; mean pulmonary artery pressure (mPAP) >20 mmHg, pulmonary artery wedge pressure (PAWP) >15 mmHg, and pulmonary vascular resistance (PVR) 20 mmHg, PAWP >15 mmHg, and PVR ≥3 WU (iii) borderline-PH group; mPAP >20 mmHg and PAWP ≤15 mmHg (iv) non-PH group; mPAP ≤20 mmHg. Multivariate Cox hazard analysis was used to investigate whether Cpc-PH was associated with cardiac outcomes.Results: The study subjects were allocated into the Ipc-PH (n = 268), Cpc-PH (n = 54), borderline-PH (n = 112), or non-PH (n = 267) groups. The Cpc-PH group was associated significantly with adverse cardiac events even after adjustment for clinically relevant confounding factors for heart failure prognosis (vs. non-PH group: HR 2.98 [95% CI 1.81–4.90],PP= 0.007).Conclusions: The new definitions of PH-LHD stratified patients into 4 categories. Long-term clinical outcomes were significantly different between the four categories, with Cpc-PH having the worst cardiac outcomes.


  • Open Access

    The Comparison of Clinical Outcomes Between Inferior ST-Elevation Myocardial Infarction with Right Ventricular Infarction Versus Without Right Ventricular Infarction

    by Masamitsu Noguchi, Kenichi Sakakura, Naoyuki Akashi, Yusuke Adachi, Yusuke Watanabe, Yousuke Taniguchi, Tatsuro Ibe, Kei Yamamoto, Hiroshi Wada, Shin-Ichi Momomura, et al.

    Right ventricular infarction (RVI) is a complication following inferior ST-elevation myocardial infarction (STEMI). The aim of the present study was to investigate the clinical outcomes of RVI in the contemporary primary percutaneous coronary intervention (PCI) era. The primary endpoint was in-hospital death, and the secondary endpoint was major adverse cardiac events (MACE), defined as the composite of cardiovascular death, re-hospitalization for heart failure, and non-fatal acute myocardial infarction (AMI). Event-free survival curves for MACE were constructed using the Kaplan-Meier method, and statistical differences between curves were assessed using the log-lank test. A total of 1354 patients with AMI were screened from January 2010 to December 2016. The final study population involved 315 patients with STEMI whose infarct related artery (IRA) was the right coronary artery (RCA). We categorized these 315 patients into the RVI group (n = 85) and the non-RVI group (n = 230). Median follow-up duration was 358 (IQR: 208-987) days. In-hospital deaths were more frequently observed in the RVI group (9.4%) than in the non-RVI group (3.0%) (P = 0.018). However, the incidence of MACE was not different between the groups (P = 0.537). In conclusion, in-hospital clinical outcomes were poorer in the RVI group than in the non-RVI group. However, mid-term MACE was not different between the two groups, suggesting the importance of aggressive acute treatment for STEMI patients with RVI.